Recombinant human (rh) IL-11, a Food and Drug Administration (FDA)–approved drug for treating thrombocytopenia (59), was initially claimed to be cardioprotective and antifibrotic (44, 45). This evidence concerns the gene IL11 and Thrombocytopenia.